Zimmer Biomet Files 8-K on Financial Results & Condition
Ticker: ZBH · Form: 8-K · Filed: Feb 8, 2024 · CIK: 1136869
| Field | Detail |
|---|---|
| Company | Zimmer Biomet Holdings, INC. (ZBH) |
| Form Type | 8-K |
| Filed Date | Feb 8, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: financial-results, debt, corporate-filing
TL;DR
**ZBH just dropped an 8-K with fresh financial results, time to check their debt and stock status!**
AI Summary
Zimmer Biomet Holdings, Inc. filed an 8-K on February 8, 2024, to report its financial results and condition, specifically mentioning its 1.164% Notes due 2027 and 2.425% Notes due 2026, along with common stock. This filing indicates the company is providing updated financial information, which is crucial for investors to assess the company's current financial health and its ability to manage its debt obligations. For shareholders, this means new data is available to evaluate the company's performance and future prospects, potentially influencing stock valuation.
Why It Matters
This filing provides investors with the latest financial data, enabling them to make informed decisions about ZBH's stock based on its current performance and debt structure.
Risk Assessment
Risk Level: low — This 8-K is a routine disclosure of financial results and condition, not indicating any immediate new risks.
Analyst Insight
Investors should review the full financial statements and exhibits referenced in this 8-K to understand the detailed results of operations and financial condition, especially concerning the mentioned debt instruments, before making any investment decisions.
Key Numbers
- 1.164% — Interest rate (for notes due 2027, indicating cost of debt)
- 2027 — Maturity year (for 1.164% notes, showing long-term debt obligations)
- 2.425% — Interest rate (for notes due 2026, indicating cost of debt)
- 2026 — Maturity year (for 2.425% notes, showing long-term debt obligations)
Key Players & Entities
- ZIMMER BIOMET HOLDINGS, INC. (company) — the registrant filing the 8-K
- February 8, 2024 (date) — date of earliest event reported and filing date
- 1.164% Notes due 2027 (dollar_amount) — a specific debt instrument of the company
- 2.425% Notes due 2026 (dollar_amount) — another specific debt instrument of the company
- Common Stock (dollar_amount) — equity class mentioned in the filing
Forward-Looking Statements
- Zimmer Biomet's stock price will remain stable as this is a routine financial disclosure. (ZIMMER BIOMET HOLDINGS, INC.) — high confidence, target: 2024-03-08
- Analysts will incorporate the new financial condition data into their models for ZBH. (ZIMMER BIOMET HOLDINGS, INC.) — high confidence, target: 2024-02-22
FAQ
What is the purpose of this 8-K filing by Zimmer Biomet Holdings, Inc.?
The purpose of this 8-K filing is to report on the company's 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits' as of February 8, 2024.
What specific financial instruments are highlighted in the filing?
The filing specifically highlights the company's '1.164% Notes Due Two Thousand Twenty Seven' and 'Two Point Four Two Five Percentage Notes Due Two Thousand Twenty Six', along with 'Common Stock'.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on February 8, 2024.
What is the company's business address and phone number as listed in the filing?
Zimmer Biomet Holdings, Inc.'s business address is 345 East Main Street, Warsaw, Indiana, 46580, and its telephone number is (574) 373-3333.
Under which SEC Act is this 8-K filed?
This 8-K is filed under the 1934 Act, as indicated by 'SEC ACT: 1934 Act' in the filing values.
Filing Stats: 569 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2024-02-08 06:37:37
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value ZBH New York Stock Exchan
Filing Documents
- zbh-20240208.htm (8-K) — 47KB
- zbh-ex99_1.htm (EX-99.1) — 1615KB
- img210921253_0.jpg (GRAPHIC) — 35KB
- 0000950170-24-012530.txt ( ) — 2047KB
- zbh-20240208.xsd (EX-101.SCH) — 135KB
- zbh-20240208_htm.xml (XML) — 7KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On February 8, 2024, Zimmer Biomet Holdings, Inc. (the "Company") issued a press release reporting its financial results for the quarter and year ended December 31, 2023. A copy of the press release is attached as Exhibit 99.1 and the information set forth therein is incorporated herein by reference and constitutes a part of this report. The information contained in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed to be "filed" with the Securities and Exchange Commission for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section and is not incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits EXHIBIT INDEX Exhibit No. Description 99.1 Press release dated February 8, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: February 8, 2024 ZIMMER BIOMET HOLDINGS, INC. By: /s/ Chad F. Phipps Name: Chad F. Phipps Title: Senior Vice President, General Counsel and Secretary